Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 392, Issue 4, pp 393–403 | Cite as

A literature analysis on anti-vascular endothelial growth factor therapy (anti-VEGF) using a bibliometric approach

  • Andy Wai Kan YeungEmail author
  • Mohamed M. Abdel-DaimEmail author
  • Abdelrahman Ibrahim Abushouk
  • Kazuaki Kadonosono


We performed the current study to assess the citation performance of research works on anti-vascular endothelial growth factor (anti-VEGF) therapy. We searched Web of Science (WoS) to identify relevant publications and analyze them with reference to their publication year, journal title, citation count, WoS category, and article type. The bibliometric software (VOSviewer) was used for citation analyses of countries and journals and to generate a term map that visualizes the recurring terms appearing in the titles and abstracts of published articles. The literature search resulted in 7364 articles, with a mean citation count of 26.2. Over half of them (50.2%) were published during the past 5 years. Original articles constituted the majority (67.8%). The publications were mainly classified into WoS categories of ophthalmology (43.2%) and oncology (20.6%). The most prolific ophthalmology and cancer journals were Investigative Ophthalmology & Visual Science (7.3%) and Cancer Research (1.4%), respectively. The correlation between journal impact factor and citation count was weak to moderate (for journals with impact factor up to 5 and 10, respectively), and open-access articles had significantly more citations than non-open-access articles (p < 0.001). The frequently targeted tumors by anti-VEGF therapy included metastatic colorectal cancer (196; 49.2 citations per article (CPA)), breast cancers (167; 37.2 CPA), and renal cell carcinoma (122; 38.2 CPA). The frequently targeted eye pathologies were age-related macular degeneration (828; 18.2 CPA), diabetic macular edema (466; 10.8 CPA), and diabetic retinopathy (358; 31.9 CPA). These results indicate that anti-VEGF therapy has a wide range of applications and its publications are highly cited.


Anti-VEGF Bibliometric Cancer Macular edema Web of Science 



citations per article


vascular endothelial growth factor


Web of Science


Author contribution

AWKY and MMAD conceived the work. AWKY acquired data. AWKY, MMAD, and AIA drafted the work. AWKY, AIA, KK, and MMAD analyzed data. MMAD and KK critically revised the work. All authors have approved the final content of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Supplementary material

210_2019_1629_MOESM1_ESM.xlsx (62 kb)
ESM 1 (XLSX 62 kb)


  1. Aalders KC, Tryfonidis K, Senkus E, Cardoso F (2017) Anti-angiogenic treatment in breast cancer: facts, successes, failures and future perspectives. Cancer Treat Rev 53:98–110Google Scholar
  2. Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M (2018) Anti-angiogenic therapy for high-grade glioma. Cochrane Database Syst Rev 11:Cd008218Google Scholar
  3. Andres-Guerrero V, Perucho-Gonzalez L, Garcia-Feijoo J, Morales-Fernandez L, Saenz-Frances F, Herrero-Vanrell R et al (2017) Current perspectives on the use of anti-VEGF drugs as adjuvant therapy in glaucoma. Adv Ther 34(2):378–395Google Scholar
  4. Brogi E, Wu T, Namiki A, Isner JM (1994) Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 90(2):649–652Google Scholar
  5. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438(7070):932–936Google Scholar
  6. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119(7):1399–1411Google Scholar
  7. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26(1):127–131Google Scholar
  8. Chua S, Qureshi AM, Krishnan V, Pai DR, Kamal LB, Gunasegaran S, Afzal MZ, Ambawatta L, Gan JY, Kew PY, Winn T, Sood S (2017) The impact factor of an open access journal does not contribute to an article’s citations. F1000Res 6Google Scholar
  9. de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ et al (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13(12):1225–1233Google Scholar
  10. Eysenbach G (2006) Citation advantage of open access articles. PLoS Biol 4(5):e157Google Scholar
  11. Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161(2):851–858Google Scholar
  12. Ferrara N, Gerber H-P, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669–676Google Scholar
  13. Ferrara N, Hillan KJ, Gerber H-P, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391–400Google Scholar
  14. Finardi U (2013) Correlation between journal impact factor and citation performance: an experimental study. J Informetr 7(2):357–370Google Scholar
  15. Group CR (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897–1908Google Scholar
  16. Heersmink R, van den Hoven J, van Eck NJ, van den Berg J (2011) Bibliometric mapping of computer and information ethics. Ethics Inf Technol 13(3):241–249Google Scholar
  17. Hopirtean C, Nagy V (2018) Optimizing the use of anti VEGF targeted therapies in patients with metastatic colorectal cancer: review of literature. Clujul Med 91(1):12Google Scholar
  18. Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Rev Clin Oncol 3(1):24–40Google Scholar
  19. Jiang Y, Mieler WF (2017) Update on the use of anti-VEGF intravitreal therapies for retinal vein occlusions. Asia Pac J Ophthalmol (Phila) 6(6):546–553Google Scholar
  20. Jubb AM, Harris AL (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11(12):1172–1183Google Scholar
  21. Kamba T, McDonald D (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96(12):1788–1795Google Scholar
  22. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly D (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246(4935):1309–1312Google Scholar
  23. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423):841–844Google Scholar
  24. Mitchell P (2011) A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin 27(7):1465–1475Google Scholar
  25. Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U et al (2014) Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev 9:CD011230Google Scholar
  26. Nicholson BP, Schachat AP (2010) A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 248(7):915–930Google Scholar
  27. Pe’Er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E (1995) Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 72(6):638–645Google Scholar
  28. Phillips HS, Hains J, Leung DW, Ferrara N (1990) Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology 127(2):965–967Google Scholar
  29. Piwowar H, Priem J, Larivière V, Alperin JP, Matthias L, Norlander B, Farley A, West J, Haustein S (2018) The state of OA: a large-scale analysis of the prevalence and impact of open access articles. PeerJ 6:e4375Google Scholar
  30. Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359(6398):845–848Google Scholar
  31. Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57(20):4593–4599Google Scholar
  32. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T et al (1995) Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55(20):4575–4580Google Scholar
  33. Rosenfeld PJ (2011) Bevacizumab versus ranibizumab for AMD. N Engl J Med 364(20):1966–1967Google Scholar
  34. Roskoski R Jr (2007) Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62(3):179–213Google Scholar
  35. Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Monés J, Richard G, Bandello F (2014) Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98(9):1144–1167Google Scholar
  36. Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359(6398):843–845Google Scholar
  37. Sitohy B, Nagy JA, Dvorak HF (2012) Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 72(8):1909–1914Google Scholar
  38. van Eck NJ, Waltman L (2009) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84(2):523–538Google Scholar
  39. Villaruz LC, Socinski MA (2015) The role of anti-angiogenesis in non-small-cell lung cancer: an update. Curr Oncol Rep 17(6):26Google Scholar
  40. Wang W-J, Chen J, Zhang X-L, Yao M, Liu X-Y, Zhou Q et al (2015) Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis. Int J Ophthalmol 8(1):138Google Scholar
  41. Yeung AWK (2018) Bibliometric study on functional magnetic resonance imaging literature (1995–2017) concerning chemosensory perception. Chemosens Percept:1–9Google Scholar
  42. Yeung AWK, Goto TK, Leung WK (2017a) A bibliometric review of research trends in neuroimaging. Curr Sci 112(4):725–734Google Scholar
  43. Yeung AWK, Goto TK, Leung WK (2017b) The changing landscape of neuroscience research, 2006–2015: a bibliometric study. Front Neurosci 11:120Google Scholar
  44. Yeung AWK, Heinrich M, Atanasov AG (2018) Ethnopharmacology—a bibliometric analysis of a field of research meandering between medicine and food science? Front Pharmacol 9:215Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Oral and Maxillofacial Radiology, Applied Oral Sciences, Faculty of DentistryThe University of Hong KongHong Kong S.A.R.China
  2. 2.Pharmacology Department, Faculty of Veterinary MedicineSuez Canal UniversityIsmailiaEgypt
  3. 3.Department of Ophthalmology and Micro-TechnologyYokohama City UniversityYokohamaJapan
  4. 4.Faculty of MedicineAin Shams UniversityCairoEgypt

Personalised recommendations